Literature DB >> 16616047

Approach to the complications of treatment for acute leukemia in the elderly.

Joel Gingerich1, Eric J Bow.   

Abstract

Acute leukemia is common in the elderly and, due to the aging population and poorer prognosis, represents a major challenge. Elderly acute leukemia patients have been arbitrarily defined as >or=55 to 65 years of age and are underrepresented in clinical trials. There are physiologic differences between elderly and non-elderly patients. A comprehensive understanding of these differences allows the development of a systematic approach to assessing the risks for treatment-related complications. Use of a comprehensive geriatric assessment (CGA), initially developed and validated in the general geriatric population, may allow more accurate assessment of the likelihood of chemotherapy-induced complications and allow for proactive risk minimization. Once complications to therapy develop, aggressive treatment is essential. Treatment related to common complications that arise from therapy will be reviewed. Further research directed at this population is required.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16616047     DOI: 10.1053/j.seminhematol.2006.01.001

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  2 in total

1.  Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes.

Authors:  Terry J Gaymes; Sydney Shall; Lee J MacPherson; Natalie A Twine; Nicholas C Lea; Farzin Farzaneh; Ghulam J Mufti
Journal:  Haematologica       Date:  2009-05       Impact factor: 9.941

2.  Clinical symptoms and chemotherapy completion in elderly patients with newly diagnosed acute leukemia: a retrospective comparison study with a younger cohort.

Authors:  Rong Hu; Yong Wu; Xiaoying Jiang; Wenteng Zhang; Le Xu
Journal:  BMC Cancer       Date:  2011-06-07       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.